News In Theranostics
Targeting Glioblastoma with Precision: The Promise of Lutetium-177 ITM-31
Thu Jul 10 2025
SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer
Thu Jul 24 2025
Improving Access to Nuclear Medicine: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
Mon Jun 30 2025
Groundbreaking Cancer Therapy Clinical Trial with U.S. Department of Energy’s Accelerator-Produced Actinium-225 Set to Begin this Summer
Wed Jun 18 2025
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
Mon Jun 30 2025
Ratio Therapeutics secures isotope supply deal with Nusano for radiopharmaceutical development
Mon Jun 23 2025
PharmaLogic Completes Acquisition of Majority Stake in Agilera Pharma AS
Mon Jun 23 2025
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
Mon Jun 23 2025
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Fri Jun 13 2025
SNMMI: PET imaging improves OMD detection in breast cancer patients
Mon Jun 23 2025
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
Wed Jun 25 2025
PanTera produces and supplies first Actinium-225 extracted from Thorium-229 in Belgium.
Thu Jun 12 2025
CLARITY PHARMACEUTICALS EXPANDS MANUFACTURING
Tue Jun 17 2025
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
Wed Jun 25 2025
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity
Tue Jun 10 2025
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany
Thu Jun 05 2025
Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma
Fri May 30 2025
Radiopharm’s HEAT Is On: First Patient Dosed in Pioneering HER2 Trial
Tue Jun 03 2025
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Mon Jun 02 2025
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Fri May 30 2025
[68Ga]Ga-PSMA-11 PET/CT and [18F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial
Wed May 28 2025
New Combination Therapy Safe and Feasible for Neuroendocrine Tumor Patients
Wed May 21 2025
Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
Thu May 01 2025
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
Mon May 19 2025
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
Mon May 12 2025
Ratio Therapeutics to construct radiopharmaceutical facility
Thu May 08 2025
Novel Radiolabeled Antibody Developed for Diagnosis and Treatment of Solid Tumors
Thu Apr 17 2025
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
Fri Apr 25 2025
SPECT/CT predicts overall survival in Pluvicto patients
Fri Apr 25 2025
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis
Mon Apr 28 2025
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Thu Apr 17 2025
Novel Radiolabeled Antibody Developed for Diagnosis and Treatment of Solid Tumors
Thu Apr 17 2025
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Wed Apr 16 2025
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
Tue Apr 15 2025
AdvanCell proudly announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
Fri Apr 11 2025
Curium enhances its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
Thu Apr 10 2025
PharmaLogic to Acquire Majority Stake in Agilera, Strengthening Global Expertise in Radiopharmaceutical Therapeutics
Wed Apr 09 2025
Akiram Therapeutics initiates Eurostars-funded collaboration to develop next-generation targeted alpha-therapeutics
Fri Apr 04 2025
FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto
Fri Mar 28 2025
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Mon Mar 17 2025
Telix Adds Lead-212 Isotope Production Capability
Thu Mar 13 2025
Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
Tue Mar 11 2025
177-Lutetium-PSMA vs Cabazitaxel: A Real-World mCRPC Study - Mike Wenzel
Mon Mar 03 2025
FES-PET shows promise staging patients with low-grade breast cancer
Tue Mar 04 2025
Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics
Thu Feb 27 2025
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Wed Feb 26 2025
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
Wed Feb 26 2025
ASCO GU 2025: Seeing Is Believing: Radiographic Criteria to Assess Response
Thu Feb 13 2025
New PET tracer developed for breast cancer
Fri Feb 14 2025
Radiopharmaceutical Industry Trends Shaping 2025
Thu Feb 20 2025
JNM Publishes Procedure Standard/Practice Guideline for Fibroblast Activation Protein PET
Fri Jan 24 2025
Dosimetry key in Lu-177 cancer therapy
Wed Feb 05 2025
Longtime manufacturer ITM's lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial
Tue Jan 28 2025
Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development
Thu Jan 16 2025
Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences
Tue Jan 28 2025
